Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... BERNARDINO, Calif., Jan. 25, 2011 Most people know ... know why they should take them or which vitamins ... are getting the vitamins they need, the Stater Bros. ... free 5-minute personal health survey.  The recommendations from this ...
... Jan. 25, 2011 Reportlinker.com announces that a ... catalogue: Emerging Regional Markets for ... The overall emerging markets for ... regions include Latin America, China, Eastern Europe, the ...
Cached Medicine Technology:Stater Bros. Introduces Free Personal Vitamin Recommendation Program 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 3Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 4Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 5
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
(Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
(Date:7/9/2014)... Keck School of Medicine of the University of ... a specific component of the immune system are ... of infection. The discovery suggests that blocking this ... human autoimmune and hyper-inflammatory diseases such as rheumatoid ... was published online on June 23 in ...
(Date:7/8/2014)... LIVERMORE, Calif. The Department of Defense,s Defense ... National Laboratory (LLNL) up to $2.5 million to ... to record and stimulate neurons within the brain ... week. , The research builds on the understanding ... in certain regions of the brain encode information, ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... unawares, leading to heart failure and even death. This ... valve// or arterial diseases and congenital heart defects, but ... in the bloodstream. ,In a paper to ... Nature Structural and Molecular Biology, a Rutgers-Newark researcher and ...
... first group of Electronic Health Record (EHR) products ... Records// Vendors Association (EHRVA) recognizes this achievement and ... accelerate EHR adoption. ,“EHRVA works to ... the significant value they provide to patients, providers, ...
... Researchers from Florida Atlantic University, the Center for Breast ... Hospital, and MeVis, The Center for Diagnostic// Systems and ... new techniques to aid clinicians in the diagnosis and ... developed and piloted a unique software platform utilizing computational ...
... in Australia to the grant of patent application to ... discovery of RNAi has been withdrawn.// This was announced ... of Massachusetts Medical School. The opposition was originally filed ... Announcement of the withdrawal will be published in Australia's ...
... insufficient oxygen supply to the heart as the critical ... a hypothermic state.// ,Writing in the July ... Physiology, researchers found no significant difference in the amount ... to one hour of severe hypothermia and rats exposed ...
... Pradesh government to stop functioning of all but one medical ... ,The court asked the state government not to ... ,The order was passed by Justice Sunil Ambawani on a ... ban on quacks in the state., ,However, the court ...
Cached Medicine News:Health News:Heart disease and strokes connected to a motor protein mechanism 2Health News:EHRVA Supports EHR Product Certification 2Health News:New Tool to Diagnose and Treat Breast Cancer 2Health News:New Tool to Diagnose and Treat Breast Cancer 3Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 2Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 3
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Knot tier...
Medicine Products: